Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| NTSKNetskope Inc | $5.73B | — | $709M | +31.7% | -$679.39M | $220.85M | $34.12M | Overvalued |
| LGNLegence Corp. | $5.75B | — | $2.55B | +21.5% | -$59.78M | $291.98M | $1.2B | Fair valued |
| BGCBGC Group, Inc. | $5.75B | 30.3× | $2.44B | +34.7% | $154.96M | $766.85M | $2B | Undervalued |
| MKTXMarketaxess Holdings Inc | $5.75B | 19.3× | $846.27M | +3.6% | $246.63M | $245.79M | $178.91M | Fair valued |
| DLBDolby Laboratories, Inc. | $5.76B | 26.1× | $1.35B | +5.9% | $255.02M | $669.39M | $47.45M | Fair valued |
| SXTSensient Technologies Corp | $5.76B | 36.6× | $1.61B | +3.5% | $134.49M | $31.02M | $763.9M | Overvalued |
| CORZCore Scientific, Inc. | $5.76B | — | $319.02M | -37.5% | -$288.62M | $1.77B | $4.41B | Fair valued |
| XENEXenon Pharmaceuticals Inc. | $5.76B | — | $7.5M | — | -$345.91M | $119.53M | $6.42M | Fair valued |
| TALTAL Education Group | $5.77B | 7.7× | $3.01B | +33.7% | $530.75M | $1.52B | $387.48M | Undervalued |
| PORPortland General Electric Co | $5.79B | 21.8× | $3.56B | +2.2% | $306M | $35M | $5.21B | Fair valued |
| MCYMercury General Corp | $5.79B | 6.2× | $29.6M | +17.5% | $541.09M | $1.7B | $962.13M | Undervalued |
| RDNTRadNet, Inc. | $5.79B | — | $2.04B | +11.5% | -$18.65M | $726.27M | $2.18B | Overvalued |
| RLIRli Corp | $5.79B | 13.3× | $1.88B | +6.3% | $403.34M | $32.1M | $318.73M | Fair valued |
| ABCBAmeris Bancorp | $5.8B | 15.6× | $1.21B | +5.7% | $412.15M | $1.2B | $50.68M | Fair valued |
| BXSLBlackstone Secured Lending Fund | $5.8B | 19.6× | $1.42B | +6.9% | $563.46M | $267.16M | $7.54B | Fair valued |
| ENVAEnova International, Inc. | $5.8B | 17.3× | $3.15B | +18.6% | $308.39M | $122.23M | $5.05B | Fair valued |
| OTEXOpen Text Corp | $5.82B | 9.6× | $5.25B | +1.5% | $643.02M | $956.02M | $5.97B | Undervalued |
| PTCTPtc Therapeutics, Inc. | $5.83B | — | $1.73B | +114.5% | $682.64M | $1.05B | $696.47M | Fair valued |
| AUBAtlantic Union Bankshares Corp | $5.85B | 12.3× | $1.37B | +68.1% | $273.72M | $990.3M | $2.01B | Fair valued |
| AGXArgan Inc | $5.86B | 33.0× | $944.61M | +8.1% | $137.77M | $364.48M | $6.39M | Overvalued |